Document is current
Any future updates will be listed below
-
Authors
Willumsen, Nicholas
Henriksen, Kim
Bager, Cecilie
Hansen Selnø, Anette T.
Mohamed, Khaled E.
Leeming, Diana J.
Skarsfeldt, Mark Alexander
Nissen, Neel I.
Pedersen, Rasmus S.
Thorlacius-Ussing, Jeppe
Dziegiel, Morten H.
Tang, Man-Hung Eric
Jørgensen, Lars N.
Diab, Hadi M. H.
Chen, Inna M.
Johansen, Julia S.
Vitorino, Philip
Sarkar, Abby
Bradshaw, Andrew
Karsdal, Morten A.
-
Funding
Funding for this research was provided by:
Kræftens Bekæmpelse (R218-A13160)
- License Information
-
More Information
Article History
Received: 8 July 2025
Accepted: 14 October 2025
First Online: 19 November 2025
Declarations
:
: NWI, KH, CB, ATHS, KEM, DJL, MKS, NIN, RSP, JTU, MAK, MHET: employed at Nordic Bioscience. KH, ATHS, KEM: employed at KeyBioscience. AS, AB, PV: employed at Bristol Myers Squibb. IC: research funding from Roche, Bristol Myers Squibb/Celgene, Genis, Varian Medical Systems, AstraZeneca and Genmab; travel and accommodations expenses from Roche, Bristol Myers Squibb/Celgene, Bayer; advisory role for Amgen, AstraZeneca, and ANOCCA. JSJ, MHD, LNJ, HMHD: declare no competing interests.
